← FDA DRUG APPROVALS

FDA ANDA · ANDA211020

BUPROPION HYDROCHLORIDE

Sponsor: GRAVITI PHARMS

APPLICATION
ANDA211020
TYPE
ANDA
ORIGINAL APPROVAL
2019-01-28
LATEST ACTION
2026-05-29
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

BUPROPION HYDROCHLORIDEPrescription
BUPROPION HYDROCHLORIDE 150MG · TABLET, EXTENDED RELEASE · ORAL
BUPROPION HYDROCHLORIDEPrescription
BUPROPION HYDROCHLORIDE 300MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2026-05-29Labeling · Supplement 29 · standardAP
2026-05-29Labeling · Supplement 28 · standardAP
2025-03-19Labeling · Supplement 25 · standardAP
2022-06-15Manufacturing (CMC) · Supplement 11 · unknownAP
2022-06-14Labeling · Supplement 12 · standardAP
2022-06-14Labeling · Supplement 9 · standardAP
2020-06-30Labeling · Supplement 4 · standardAP
2019-01-28UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →